Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials

Vaccine

Volumn 25, Issue 18, 2007, Pages 3517-3523

  Mehrishi, Jitendra N ^a   Szabó, Miklós ^b   Bakács, Tibor ^c,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Institute of Isotopes   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d The Cambridge Chronic Hepatitis AIDS New Treatment Strategy Development Initiative   (United Kingdom)

Author keywords

Clinical disaster; Cytokine storm; mAb; Monoclonal antibodies; Safety; Vaccine trials

Indexed keywords

DISULFIDE; GALACTOSE; MONOCLONAL ANTIBODY CD28; PLACEBO; SIALIDASE; TGN 1412; THIOL; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL INTERACTION; CELL MIGRATION; CELL SURFACE; CELL WALL; CLINICAL STUDY; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG FATALITY; DRUG RECEPTOR BINDING; DRUG SAFETY; ELECTROPHORETIC MOBILITY; ENZYME RELEASE; HUMAN; MONOCYTE; NEUTROPHIL; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; PLASMA CELL; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINE FAILURE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; CLINICAL TRIALS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; LYMPHOCYTE ACTIVATION; MALE; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINES;

EID: 34247128123     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.078     Document Type: Article

References (40)

1. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 10 (2006) 1018-1028
2. Marshall E. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science 311 5768 (2006) 1688-1689
3. Hünig T., and Dennehy K. CD28 superagonists: mode of action and therapeutic potential. Immunol Lett 100 1 (2005) 21-28
4. Beyersdorf N., Gaupp S., Balbach K., Schmidt J., Toyka K.V., Lin C.H., et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202 3 (2005) 445-455
5. Vitetta E.S., and Ghetie V.F. Immunology considering therapeutic antibodies. Science 313 5785 (2006) 308-309
6. Beyersdorf N., Hanke T., Kerkau T., and Hünig T. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis 64 Suppl 4 (2005) iv91-iv95
7. Luhder F., Huang Y., Dennehy K.M., Guntermann C., Muller I., Winkler E., et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 197 8 (2003) 955-966
8. Kenter M.J.H., and Cohen A.F. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368 (2006) 1887-2391
9. Duff G, et al. Expert Scientific Group [ESG] on Phase One Clinical Trials, Interim report; 2006. http://www.dh.gov.uk/assetRoot/04/13/75/69/04137569.pdf. (GENERIC) Ref Type: Electronic Citation, 2002.
10. Gelderman K.A., Hultqvist M., Holmberg J., Olofsson P., and Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. PNAS 103 34 (2006) 12831-12836
11. Mehrishi J.N. Molecular aspects of the mammalian cell surface. In: Butler J.A.V., and Noble D. (Eds). Prog. Biophys. Mol. Biol. vol. 25 (1972), Pergamon Press, Oxford 1-70
12. Mehrishi J.N., and Grassetti D.R. Sulphydryl groups on the surface of intact Ehrlich ascites tumour cells, human blood platelets and lymphocytes. Nature 224 5219 (1969) 563-564
13. Mehrishi J.N., and Butterworth A.E. Murine ascites tumour cells and lymphocytes. Effect of lysolecithin, organic mercurials and an anti-tumoral agent on the cell membrane permeability. Eur J Cancer 5 1 (1969) 5-14
14. Balázs M., Matkó J., Szöllösi J., Mátyus L., Fulwyler M.J., and Damjanovich S. Accessibility of cell surface thiols in human lymphocytes is altered by ionophores or OKT-3 antibody. Biochem Biophys Res Commun 140 3 (1986) 999-1006
15. Ryser H.J., Levy E.M., Mandel R., and DiSciullo G.J. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci USA 91 10 (1994) 4559-4563
16. Barbouche R., Miquelis R., Jones I.M., and Fenouillet E. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. J Biol Chem 278 5 (2003) 3131-3136
17. Born G.V.R. The platelet membrane and its function. In: Deutsch E., Gerlach E., and Moser K. (Eds). Stoffwechsel und Membranpermeabilität von Erythrozyten und Thrombozyten. [Metabolism and membrane Permeability of Erythrocytes and Thrombocytes] (1968), Georg Thieme Verlag, Stuttgart 294-301 (1st International Symposium, Vienna, June 17-20, 1968)
18. Venuprasad K., Parab P., Prasad D.V., Sharma S., Banerjee P.R., Deshpande M., et al. Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression. Eur J Immunol 31 5 (2001) 1536-1543
19. Spangenberg P., and Crawford N. Surface membrane electrokinetic properties of polymorphonuclear leucocytes: subpopulation heterogeneity and phagocytic competence. J Cell Biochem 34 4 (1987) 259-268
20. Eggleton P., Crawford N., and Fisher D. Fractionation of human neutrophils into subpopulations by countercurrent distribution: surface charge and functional heterogeneity. Eur J Cell Biol 57 2 (1992) 265-272
21. Eggleton P., Fisher D., and Crawford N. Heterogeneity in the circulating neutrophil pool: studies on subpopulations separated by continuous flow electrophoresis. J Leukoc Biol 51 6 (1992) 617-625
22. Mehrishi J.N., and Zeiller K. T and B lymphocytes: striking differences in surface membranes. Br Med J 1 5904 (1974) 360-362
23. Mehrishi J.N., and Zeiller K. Surface molecular components of T and B lymphocytes. Europ J Immunol 4 (1974) 474-478
24. Mehrishi J.N., and Wioland M. Electrokinetic charge approach for probing events at the membrane level of single viable cells. In: Lambert P.P., Bergmann P., and Beauwens R. (Eds). The Pathogenicity of Cationic Proteins (1983), Raven Press, New York 41-54
25. Venuprasad K., Chattopadhyay S., and Saha B. CD28 signaling in neutrophil induces T-cell chemotactic factor(s) modulating T-cell response. Hum Immunol 64 1 (2003) 38-43
26. Manca F. Galactose receptors and presentation of HIV envelope glycoprotein to specific human T cells. J Immunol 148 7 (1992) 2278-2282
27. Farrar G.H., Holz G., and Uhlenbruck G. Glycoproteins containing peanut-agglutinin receptors from human-peripheral-blood T-lymphocyte plasma membranes. Eur J Biochem 121 1 (1981) 237-241
28. Verheijen F.W., Janse H.C., van Diggelen O.P., Bakker H.D., Loonen M.C., Durand P., et al. Two genetically different MU-NANA neuraminidases in human leucocytes. Biochem Biophys Res Commun 117 2 (1983) 470-478
29. Nojiri N., Takaku F., Tetsuka T., and Saito M. Stimulation of sialidase activity during cell differentiation of human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 104 4 (1982) 1239-1246
30. Cross A.S., and Wright D.G. Mobilization of sialidase from intracellular stores to the surface of human neutrophils and its role in stimulated adhesion responses of these cells. J Clin Invest 88 6 (1991) 2067-2076
31. Mehrishi J.N., and Bauer J. Electrophoresis of cells and the biological relevance of surface charge. Electrophoresis 23 13 (2002) 1984-1994
32. Bhogal N., and Combes R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. Altern Lab Anim 34 2 (2006) 225-239
33. Hjelm F., Carlsson F., Getahun A., and Heyman B. Antibody-mediated regulation of the immune response. Scand J Immunol 64 3 (2006) 177-184
34. De Smedt T., Pajak B., Muraille E., Lespagnard L., Heinen E., De Baetselier P., et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184 4 (1996) 1413-1424
35. Lespagnard L., Mettens P., De Smedt T., Bazin H., Urbain J., Leo O., et al. The immune response induced in vivo by dendritic cells is dependent on B7-1 or B7-2, but the inhibition of both signals does not lead to tolerance. Int Immunol 10 3 (1998) 295-304
36. Margulies D.H. CD28, costimulator or agonist receptor?. J Exp Med 197 8 (2003) 949-953
37. Travis K. Deciphering immunology's dirty little secret. Can toll-like receptor targeted immune adjuvants save vaccinology?. The Scientist 21 (2007) 46 (GENERIC) Ref Type: Electronic Citation
38. Querec T., Bennouna S., Alkan S., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203 2 (2006) 413-424
39. Schneider C.K., Kalinke U., and Lower J. TGN1412-a regulator's perspective. Nat Biotechnol 24 5 (2006) 493-496
40. Wadman M. London's disastrous drug trial has serious side effects for research. Nature 440 7083 (2006) 388-389